SIEMENS Healthineers

New levels of productivity and digitalization for the clinical lab

Diagnostics

Deepak Nath
President Laboratory Diagnostics

Safe Harbour Statement

This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be bound by the following limitations.
This presentation has been prepared for information purposes only and the information contained herein (unless otherwise indicated) has been provided by Siemens Healthineers AG. It does not constitute or form part of, and should not be construed as, an offer of, a solicitation of an offer to buy, or an invitation to subscribe for, underwrite or otherwise acquire, any securities of Siemens Healthineers AG or any existing or future member of the Siemens Healthineers Group (the "Group") or Siemens AG, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Siemens Healthineers AG, any member of the Group or Siemens AG or with any other contract or commitment whatsoever. This presentation does not constitute a prospectus in whole or in part, and any decision to invest in securities should be made solely on the basis of the information to be contained in a prospectus and on an independent analysis of the information contained therein.
Any assumptions, views or opinions (including statements, projections, forecasts or other forward-looking statements) contained in this presentation represent the assumptions, views or opinions of Siemens Healthineers AG, unless otherwise indicated, as of the date indicated and are subject to change without notice.
Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these assumptions, views or opinions in light of developments which differ from those anticipated.
All information not separately sourced is from internal company data and estimates. Any data relating to past performance contained herein is no indication as to future performance. The information in this presentation is not intended to predict actual results, and no assurances are given with respect thereto.
The information contained in this presentation has not been independently verified, and no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information contained herein and no reliance should be placed on it. None of Siemens Healthineers AG or any of its affiliates, advisers, affiliated persons or any other person accept any liability for any loss howsoever arising (in negligence or otherwise), directly or indirectly, from this presentation or its contents or otherwise arising in connection with this presentation. This shall not, however, restrict or exclude or limit any duty or liability to a person under any applicable law or regulation of any jurisdiction which may not lawfully be disclaimed (including in relation to fraudulent misrepresentation).
This document contains statements related to our future business and financial performance and future events or developments involving Siemens Healthineers that may constitute forward-looking statements. These statements may be identified by words such as "expect", "forecast", "anticipate", "intend", "plan", "believe", "seek", "estimate", "will", "target" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens Healthineers' management, of which many are beyond Siemens Healthineers' control. As they relate to future events or developments, these statements are subject to a number of risks, uncertainties and factors, including, but not limited to those described in the respective disclosures. Should one or more of these risks, uncertainties or factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Siemens Healthineers may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement.
This document includes – in the applicable financial reporting framework not clearly defined – supplemental financial measures (financial key performance indicators) that are or may be alternative performance measures (non-GAAP measures). These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers' net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its half-year consolidated financial statements and consolidated financial statements. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, which may therefore not be comparable.
Please find further explanations regarding our financial key performance indicators in chapter "A.2 Financial performance system" and in the notes to the consolidated financial statements note 29 "Segment information" in the Annual Report 2019 of Siemens Healthineers. Additional information is also included in the Quarterly Statement. These documents can be found under the following internet link https://www.corporate.siemens-healthineers.com/investor-relations/presentations-financial-publications. As of beginning of fiscal year 2020, Siemens Healthineers applies the accounting standard IFRS 16, Leases. Comparative figures for the preceding fiscal year were not adjusted. Instead, the overall insignificant transition effects were recognized in equity as of October 1, 2019.

Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.
Due to technical reasons, there may be discrepancies in formatting of the accounting data included in this document and made publicly available according to applicable legal rules.
The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice.

Diagnostics – Building from a leading position with the broadest portfolio in the industry

SIEMENS Healthineers

Strong positions …

Laboratory Diagnostics | Automation | Point-of-Care

… in an attractive market …

€28bn+	>5%
Market Size[1]	Market CAGR[1]

… with global scale

300k+	135+
Global Installed Base[2]	Number of Countries[2]

Decentralized settings

Connected point-of-care solutions

Urinalysis

Blood Gas

HbA1C

Cardiac

Informatics

Workflow excellence

Clinical excellence

Digitalization

End-to-End Solutions

Centralized settings

Automated, high throughput solutions

Atellica Solution (CC/IA)



Automation/IT



Hematology

Coagulation

Urinalysis

1 2019 BBC Annual IVD Market Book in USD and calendar year, excludes Molecular Diagnostics **2** Internal data

Atellica® Solution delivers tangible value to customers (catalyst for growth)

SIEMENS Healthineers

Customized configurations
to meet individual lab needs

33%
fewer analyzers [4]

>35%
Competitive wins

Seamless integration of **emergency and routine testing**



86%
fewer operators[4]

Advanced automated workflow
to reduce manual interventions

73%
less hands-on time [4]

Highest immunoassay **productivity** [1]

Remote proactive monitoring and support

>80%
Mega Lab[2] competitive win rate with TLA[3]

Quest Diagnostics · HERMES PARDINI · HUS

Designed to meet evolving needs of customers… + **…with good uptake in the market…** = **…and tangible customer impact.**

Product availability may vary from country to country and is subject to varying regulatory requirements
1) Based on tests per hour per m^2 when compared to leading competitive modular immunoassay instrument 2) Labs processing in excess of ~30 k tubes/day
3) TLA = Total Lab Automation 4) The outcomes obtained by individual Siemens Healthineers customers were realized in the customers unique setting. Since there is no typical laboratory, and many variables exist, there can be no guarantee that others will achieve the same results Source: Laboratory Diagnostics

COVID-19 impacted performance – improvement expected in FY21

Grow | Expand | Elevate

Delivering on the promise of Atellica Solution



Performance in FY20 significantly impacted by COVID

- Severe **decline in routine care testing**, partial recovery in Q4
- **Continued "investment" in service** and **maturing Atellica** systems: foundational to margin improvement in FY21, high seeding rates for Atellica instruments

Outlook FY21: improvement expected in both top and bottom line

- **Routine care recovers** but remains below 2019 levels
- Good progress in **maturing of Atellica platform**
- Improved **factory utilization**
- **Strengthened leadership team**

Our portfolio innovations will deliver the lab of the future

Grow | **Expand** | **Elevate**

Lead in workflow and
achieve clinical excellence

Positioning ourselves for the **future**

- Deliver further **Atellica innovations** incl. Mid-Volume system (CI1900[1])
- Launch assays to continue **menu enrichment**

Innovating in **workflow**

- Enhance and expand **Atellica Solution IT**
- Strengthen **laboratory automation** offerings

1 In development. Future availability cannot be guaranteed.

Best-in-class testing for COVID-19

SIEMENS Healthineers

25 critical care tests for COVID-19 patients including **D-Dimer, IL-6*, SAA*, CRP, Procalcitonin (PCT), TnIH**

Do I have COVID-19?

Molecular SARS-CoV-2 test kit**
- FDA EUA-authorized, CE-marked, WHO EUL
- 100% positive, 100% negative agreements[1]

Rapid SARS-CoV-2 POC Antigen Test[2]
- CE-marked; under FDA review for EUA
- Portable visual read, 15-min. TAT



Total Antibody Assay: IgG/IgM**
- 100% sensitivity, 99.8% specificity[3]
- Utilizes the spike protein to detect total antibodies to block the virus entry into human cells

Both tests are CE-marked and FDA EUA-authorized and run on one of largest installed base of high-throughput automated analyzers worldwide

IgG Quantitative Antibody Assay**
- 100% sensitivity, 99.9% specificity, [3]
- **Measures levels of IgG neutralizing antibodies** to the spike protein, enabling tracking of changes over time

JRC · CDC Centers for Disease Control and Prevention · SIEMENS Healthineers · Public Health England · University of Oxford · ASCEND

Importantly, Anand and colleagues chose a good test for their survey. The Siemens lab-based spike-protein-receptor-binding domain total antibody chemi-luminescence assay adopted by the authors was the best-performing platform in the largest external appraisal of commercial assays to date, in terms of both sensitivity and specificity.[5]

THE LANCET

Do I have antibodies to the SARS-CoV-2 virus?

*Not available for sale in the U.S.
**These SARS-CoV-2 molecular and serology tests have not been FDA cleared or approved. These tests have been authorized by FDA under an EUA for use by authorized laboratories. The molecular test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The serology test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary from country to country and is subject to varying regulatory requirements.
1) In method comparison studies, FTD SARS-CoV-2 has shown Positive Percent Agreement: 100% (91.8-100, 95% CI) and Negative Percent Agreement: 100% (88.7-100, 95% CI) when tested in Copan eSwab nasopharyngeal and oropharyngeal swabs.
2) CE-IVD labeled for diagnostic use in the EU. Research Use Only (RUO) in the U.S.
3) For samples collected ≥14 days after positive PCR result.
5) www.thelancet.com Published online September 25, 2020 https://doi.org/10.1016/S0140-6736(20)32006-7 and Clarke C, Prendecki M, Dhutia A, et al. High prevalence of asymptomaticCOVID-19 infection in hemodialysis patients detected using serologic screening. *J Am Soc Nephrol* 2020; 31: 1969–75. Commentary from Barnaby Flower, Christina Atchison Department of Infectious Disease, Faculty of Medicine, Imperial College London